On Feb. 5, drugstore chain CVS Caremark announced that it will stop selling tobacco products.It’s a big deal. Here’s why.It signals a step towards more businesses saying, “It’s wrong. So we’re ...

For 2025, Barclays estimates market forecasts include expectations of 110 basis points in Medicare margin expansion, which is on the lower end of CVS’s target range of 100-200 bps.

That shows the power of CVS’ market saturation; it pushed Hyrimoz through every arm of its business. CVS said the list price of Hyrimoz is 81% cheaper than brand-name Humira.

Deep-pocketed investors have adopted a bullish approach towards CVS Health (NYSE:CVS), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

The contract, though sizable, is likely immaterial to CVS’ earnings. But it moves the company in a positive direction as it ...

CVS’s stock surges toward a one-year high after profit and revenue beat expectations, amid strength in the pharmacy business, and the full-year outlook was raised. CVS Health’s Aetna to exit ...

CVS Health (CVS) closed the most recent trading day at $61.96, moving -2.12% from the previous trading session. This change lagged the S&P 500's 0.01% loss on the day. Elsewhere, the Dow lost 0.32%, ...

CVS (CVS) Pharmacy has unveiled Well Market, its new private-label brand offerings for snacks, beverages, and groceries. Read more here.

Barclays upgraded CVS Health Inc (NYSE:CVS) on higher Pharmacy & Consumer Wellness (PCW) estimates as headwinds are offset by share gains, with further upside potential from CostVantage. Despite ...